MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive antibody targets cancer before stem cell transplant in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) that seeks out and attacks cancer cells, followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has returned or not responded to treatment. The goal is to find the …
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radioactive antibody could boost stem cell transplant success in tough leukemias
Disease control Recruiting nowThis study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough blood cancers? early trial launches
Disease control Recruiting nowThis early-stage study tests an experimental drug called APL-4098, alone or with standard treatments, in adults with acute myeloid leukemia (AML) or related blood disorders. The goal is to find a safe dose and see if it shrinks cancer. About 100 people will take part.
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune booster: personalized NK cells aim to wipe out blood cancer after transplant
Disease control Recruiting nowThis phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could removing certain immune cells prevent a deadly transplant complication?
Disease control Recruiting nowThis study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cocktail of 5 drugs targets tough leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of five drugs (fludarabine, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin) in 270 people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome that have specific genetic changes. The goal…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo aims to control rare blood cancer in High-Risk patients
Disease control Recruiting nowThis study tests a combination of two drugs, azacitidine and enasidenib, in people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if the drugs can stop cancer growth and improve outcomes. …
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New test aims to predict cancer return after bone marrow transplant
Knowledge-focused Recruiting nowThis study looks at whether detecting MDS stem cells using a special lab test (flow cytometry) can predict if the disease will come back after a stem cell transplant. Researchers will follow 163 MDS patients for one year after transplant to see if this method is better than curre…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC